07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

TheraTech, P&G sales and marketing update

P&G began selling THRT's Alora estrogen replacement therapy patch. The patch, which is indicated to treat moderate-to-severe vasomotor menopausal symptoms, is available in three dosage strengths - 0.05, 0.075 and 0.1 mgs. Price wasn't disclosed....
07:00 , Apr 15, 2002 |  BC Week In Review  |  Clinical News

Alora estradiol transdermal system regulatory update

The FDA granted WPI marketing approval for Alora to prevent postmenopausal osteoporosis. Alora already is marketed to treat moderate-to-severe vasomotor symptoms associated with menopause. Watson Pharmaceuticals Inc. (WPI), Corona, Calif.   Product: Alora estradiol transdermal...
07:00 , Oct 4, 1999 |  BC Week In Review  |  Company News

P&G, Watson sales and marketing update

Watson's TheraTech Inc. subsidiary (Salt Lake City, Utah) reacquired marketing rights from P&G to its Alora estradiol transdermal system for female hormone replacement, and an estradiol/progestin combination patch. P&G retains marketing rights to TheraTech's line...
07:00 , May 27, 1997 |  BioCentury  |  Finance

A tumble in the U.K.

A tumble in the U.K. CTP slipped 289p to 341p on 7.2 million shares on Wednesday after a Phase III trial of a monoclonal antibody licensed by...
08:00 , Dec 23, 1996 |  BC Week In Review  |  Clinical News

TheraTech regulatory update

The FDA approved THRT's Alora estrogen replacement therapy patch to treat moderate-to-severe vasomotor menopausal symptoms. Alora delivers estradiol continuously over the twice-weekly dosing period. The patch is available in three dosage strengths 0.05, 0.075, and...